Literature DB >> 8942880

Prognosticators for visual outcome in sarcoid uveitis.

M R Dana1, J Merayo-Lloves, D A Schaumberg, C S Foster.   

Abstract

PURPOSE: The purpose of the study is to delineate the visual prognosticators in sarcoid-associated uveitis given the current standards of care.
METHODS: The records of 60 patients with sarcoid-associated uveitis who were observed for at least 6 months were studied retrospectively. Multivariate regression models using the generalized estimating equations approach to adjust for the correlation between fellow eyes were applied to determine disease, patient, and treatment characteristics that altered the odds of visual rehabilitation.
RESULTS: One hundred twelve eyes of 43 women and 17 men who met the inclusion criteria were identified. Seventy-seven percent of patients were white, 15% black, and 8% of Hispanic origin. Uveitis developed in the patients at a mean age of 42 (range, 4-82) years. Of the 112 affected eyes, 81% had granulomatous and 15% nongranulomatous uveitis. Most patients (66%) had anterior or intermediate uveitis alone. Ninety-one percent had chronically smoldering disease; another 7% had recurrent flares, and only 1 patient had a monophasic acute course to her uveitis. Vision-threatening complications developed in many patients, including 58% in whom cystoid macular edema developed and 25% in whom media opacities developed, requiring cataract surgery or vitrectomy or both. Overall, 34% of treated eyes and 51% of patients had final visual acuities that were superior to their acuities at presentation. The factors most significantly associated with a final visual acuity of worse than 20/40 after controlling for potential confounders were as follows: delay in presentation to a subspecialist (odds ratio [OR] = 2.94, P = 0.05), total duration of uveitis (OR = 1.04, P = 0.09), development of cystoid macular edema (OR = 0.37, P = 0.07) or glaucoma (OR = 4.54, P = 0.02), presence of intermediate (OR = 5.00, P = 0.01) or posterior uveitis (OR = 8.33, P = 0.04), and systemic steroid use (OR = 0.30, P = 0.03) were the parameters most strongly correlated with a lack of visual acuity improvement. Delay in presentation to a subspecialist (OR = 20.00, P = 0.01), development of glaucoma (OR = 50.00, P = 0.005), presence of intermediate (OR = 25.00, P = 0.02) or posterior uveitis (OR = 50.00, P = 0.02), black race (OR = 11.11, P = 0.02), (log) visual acuity at presentation (OR = 0.05, P = 0.0001), and use of systemic steroids (OR = 0.07, P = 0.02).
CONCLUSION: Multivariate outcomes analysis, particularly after correcting for the correlation between fellow eyes, is a useful analytic tool for optimization of standards of care and for disease risk stratification to aid both physicians and patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8942880     DOI: 10.1016/s0161-6420(96)30417-x

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  37 in total

1.  Quality of life in sarcoidosis: comparing the impact of ocular and non-ocular involvement of the disease.

Authors:  Leorey N Saligan; Grace Levy-Clarke; Tongtong Wu; Lisa J Faia; Keith Wroblewski; Steven Yeh; Robert B Nussenblatt; H Nida Sen
Journal:  Ophthalmic Epidemiol       Date:  2010-08       Impact factor: 1.648

Review 2.  Ocular Sarcoidosis.

Authors:  Sirichai Pasadhika; James T Rosenbaum
Journal:  Clin Chest Med       Date:  2015-12       Impact factor: 2.878

3.  Outcome of phacoemulsification in patients with uveitis.

Authors:  M A Elgohary; P J McCluskey; H M A Towler; N Okhravi; R P Singh; R Obikpo; S S Lightman
Journal:  Br J Ophthalmol       Date:  2007-01-17       Impact factor: 4.638

Review 4.  Disease Burden and Variability in Sarcoidosis.

Authors:  Alicia K Gerke; Marc A Judson; Yvette C Cozier; Daniel A Culver; Laura L Koth
Journal:  Ann Am Thorac Soc       Date:  2017-12

Review 5.  Current approach in the diagnosis and management of panuveitis.

Authors:  Reema Bansal; Vishali Gupta; Amod Gupta
Journal:  Indian J Ophthalmol       Date:  2010 Jan-Feb       Impact factor: 1.848

6.  Diagnostic yield of vitreous biopsy in presumed sarcoidosis-related posterior segment inflammation.

Authors:  Adrienne W Scott; Prithvi Mruthyunjaya; Rex M McCallum; Glenn J Jaffe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-03-21       Impact factor: 3.117

Review 7.  Immunosuppression for the Uveitides.

Authors:  Douglas A Jabs
Journal:  Ophthalmology       Date:  2017-09-20       Impact factor: 12.079

8.  Association of complement factor H tyrosine 402 histidine genotype with posterior involvement in sarcoid-related uveitis.

Authors:  Ian A Thompson; Baoying Liu; H Nida Sen; Xiadong Jiao; Robert Katamay; Zhiyu Li; Mengjun Hu; Fielding Hejtmancik; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2013-03-14       Impact factor: 5.258

9.  Risk factors for loss of visual acuity among patients with uveitis associated with juvenile idiopathic arthritis: the Systemic Immunosuppressive Therapy for Eye Diseases Study.

Authors:  Anthony C Gregory; John H Kempen; Ebenezer Daniel; R Oktay Kaçmaz; C Stephen Foster; Douglas A Jabs; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne
Journal:  Ophthalmology       Date:  2012-10-11       Impact factor: 12.079

10.  Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Authors:  José Luis Callejas-Rubio; Lourdes López-Pérez; Norberto Ortego-Centeno
Journal:  Ther Clin Risk Manag       Date:  2008-12       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.